Last reviewed · How we verify

NCT06304155

Application of FDG Combined With FAPI PET Dual Imaging in the Diagnosis and Staging of Oropharyngeal and Laryngeal Cancer

Status unknown Last updated 15 March 2024
What this trial tests

trial testing Diagnostic efficacy,SUV in Cancer in 40 participants. Status unknown.

Timeline
1 January 2024
Primary endpoint
1 January 2026
1 January 2026

Quick facts

Lead sponsorDaping Hospital and the Research Institute of Surgery of the Third Military Medical University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment40
Start date1 January 2024
Primary completion1 January 2026
Estimated completion1 January 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

According to statistics, in 2020, new head and neck malignancies in the world accounted for 4.9% (931931 cases) of malignant tumors in the whole body, and the new death cases were 467125, accounting for 4.7% of malignant tumors in the whole body. The high incidence rate and mortality brought great burden to the medical system. In addition, due to various types of head and neck cancer, hidden location, impact on function and quality of life, and low overall survival rate, this type of disease has seriously threatened human health and social development. The incidence of oropharyngeal cancer and laryngeal cancer is more subtle. Traditional examination methods include CT(computer tomography), MR(magnetic resonance), and laryngoscopy, but they cannot make accurate judgments on the systemic TNM(primary tumor, regional nodes, metastasis) staging of oropharyngeal cancer and laryngeal cancer. 18F-FDG(18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET/CT examination can better diagnose and stage compared to traditional examination methods. However, due to the interference of more inflammatory lesions or physiological uptake in the pharynx, the false positive rate of 18F-FDG PET/CT examination is significantly increased, 18F-FAPI(18F-fibroblast activation protein inhibitors) is a novel broad-spectrum tumor imaging agent that can be specifically uptake by fibroblasts in the tumor microenvironment, and has lower physiological uptake and acute inflammatory lesion uptake in the larynx. 18F-FAPI PET/CT examination can more accurately stage tumors throughout the body than 18F-FDG PET/CT examination. Combined with PET/MR local scanning, it will further improve the accuracy of T and N staging of local tumors. Therefore, It is of great significance for clinical diagnosis and treatment to effectively and reliably determine the systemic TNM staging of oropharyngeal and laryngeal cancer through non-invasive methods.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Head-to-head comparison of [<sup>18</sup>F]FAPI-42 and [<sup>18</sup>F]FDG PET/CT in the evaluation of laryngeal squamous cell carcinoma.
    Xia R, Wang X, Cheng J, Li X, et al · · 2025 · cited 1× · PMID 40055207 · DOI 10.1007/s00259-025-07180-8

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06304155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing